AUTL News and Press, Autolus Therapeutics plc From 11/03/21

Autolus Therapeutics (NASDAQ:AUTL): Q3 GAAP EPS of -$0.47 beats by $0.04. Revenue of $0.24M (-64.7% Y/Y) misses by $0.01M. Press Release For further details see: Autolus Therapeutics EPS beats by $0.04, misses on revenue

LONDON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2021. ...

AAWW, ACLS, ACRE, AGIO, AMRN, AMRX, ATH, ATY, AUPH, AUTL, AVA, BCRX, BDC, BDSI, BGCP, BIP, OTCPK:BMWYY, BR, BRSP, BWA, CDW, CIM, CIO, CLH, CLVS, CPRI, CRL, CRTO, CSTE, CTRA, CVE, CVS, CWH, DFIN, DISCA, OTCQX:DLAKF, OTCPK:DNNGY, DNOW, EAT, EMR, ES, ETR, EVRG, EVRI, EXC, EXPI, EYPT, FDP, FUN, F...

Autolus Therapeutics (NASDAQ:AUTL) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is -$0.51 and the consensus Revenue Estimate is $0.25M (+4.2% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions and...

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights...

Although shares of CRISPR Therapeutics (CRSP -6.4%) have fallen since yesterday's after-the-bell announcement, its gene editing peers have not been impacted. Those results were from the company’s early-stage trial of its CAR-T cell therapy CTX110. Autolus Therapeutics (AUTL +...

A symmetrical triangle pattern has formed in the chart of Autolus Therapeutics PLC (AUTL). The stock is expected to either break through its resistance line or fall through its support level. Read more to learn how to be ready for a potential breakout or breakdown. Autolus Therapeutics PL...

With a list of 62 recent IPOs making entry to the Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 recalibrations, we discuss the recently-IPOd healthcare stocks joining the index. Following up on a previous article on biotech stocks in the group, in...

LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that planning approval has been granted to build the Company’s new manufacturing...

LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Direc...